Michelle L Varney Selected Research

Interleukin-8B Receptors

1/2020	IL-17-CXC Chemokine Receptor 2 Axis Facilitates Breast Cancer Progression by Up-Regulating Neutrophil Recruitment.
3/2019	CXCR2: A Novel Mediator of Mammary Tumor Bone Metastasis.
4/2010	Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma.
2/2006	Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma.
1/2004	Constitutive expression of growth regulated oncogene (gro) in human colon carcinoma cells with different metastatic potential and its role in regulating their metastatic phenotype.
1/2003	Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michelle L Varney Research Topics

Disease

34	Neoplasms (Cancer) 03/2022 - 11/2002
21	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2003
11	Melanoma (Melanoma, Malignant) 12/2012 - 04/2002
10	Multiple Myeloma 03/2022 - 01/2017
9	Breast Neoplasms (Breast Cancer) 01/2020 - 01/2009
3	Inflammation (Inflammations) 01/2020 - 01/2005
3	Osteolysis 05/2010 - 01/2009
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 09/2010
2	Hypoxia (Hypoxemia) 11/2005 - 09/2002
1	Immunoglobulin Light-chain Amyloidosis 03/2022
1	Rare Diseases (Rare Disease) 03/2022
1	Adenocarcinoma 01/2019
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 12/2016
1	Type 2 Diabetes Mellitus (MODY) 05/2009
1	Hemangiosarcoma (Angiosarcoma) 05/2009
1	Hyperlipidemias (Hyperlipidemia) 05/2009
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 08/2007
1	Prostatic Neoplasms (Prostate Cancer) 01/2007
1	Lymphatic Metastasis 10/2005
1	Infections 01/2005
1	Colonic Neoplasms (Colon Cancer) 01/2004
1	Carcinoma (Carcinomatosis) 01/2004

Drug/Important Bio-Agent (IBA)

11	LigandsIBA 01/2020 - 01/2003
9	Proteins (Proteins, Gene)FDA Link 01/2018 - 04/2002
8	Farnesyltranstransferase (Farnesyltransferase)IBA 02/2022 - 01/2017
7	Messenger RNA (mRNA)IBA 03/2014 - 09/2002
6	Interleukin-8B ReceptorsIBA 01/2020 - 01/2003
5	Chemokine ReceptorsIBA 01/2020 - 04/2010
5	ChemokinesIBA 01/2020 - 03/2003
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2015 - 09/2002
5	Interleukin-8 (Interleukin 8)IBA 01/2005 - 04/2002
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2015 - 09/2002
4	Small Interfering RNA (siRNA)IBA 03/2014 - 10/2005
3	Pharmaceutical PreparationsIBA 03/2022 - 03/2016
3	TriazolesIBA 01/2021 - 11/2019
3	Diphosphonates (Bisphosphonates)IBA 01/2021 - 11/2019
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2020 - 05/2013
3	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 05/2013
3	Vascular Endothelial Growth Factor CIBA 01/2015 - 10/2005
2	Peptides (Polypeptides)IBA 03/2022 - 01/2007
2	EnzymesIBA 01/2021 - 10/2019
2	Terpenes (Terpenoids)IBA 01/2021 - 01/2021
2	CytokinesIBA 01/2020 - 01/2020
2	Semaphorins (Semaphorin)IBA 12/2018 - 09/2010
2	Antisense OligonucleotidesIBA 05/2010 - 01/2009
2	Transforming Growth Factor beta (TGF-beta)IBA 05/2010 - 01/2009
2	Neutralizing AntibodiesIBA 01/2009 - 11/2005
2	Receptor Activator of Nuclear Factor-kappa B (TRANCE-R)IBA 01/2009 - 01/2009
2	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 11/2005 - 10/2005
2	Conditioned Culture MediaIBA 11/2005 - 11/2002
2	Macrophage Colony-Stimulating FactorIBA 11/2005 - 11/2002
2	Capsaicin (Zostrix)FDA Link 09/2002 - 04/2002
2	NF-kappa B (NF-kB)IBA 09/2002 - 04/2002
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2002 - 04/2002
1	melflufenIBA 03/2022
1	Alkylating AgentsIBA 03/2022
1	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 03/2022
1	AminopeptidasesIBA 03/2022
1	Amyloid (Amyloid Fibrils)IBA 03/2022
1	Proteasome InhibitorsIBA 02/2022
1	O,O-diisopropyl-S-benzylthiophosphate (IBP)IBA 01/2021
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021
1	Interleukin-17 ReceptorsIBA 01/2020
1	Interleukin-17 (Interleukin 17)IBA 01/2020
1	Alkenes (Olefins)IBA 11/2019
1	CaspasesIBA 01/2019
1	IronIBA 01/2019
1	hydroxide ionIBA 01/2019
1	TropoloneIBA 01/2019
1	MucinsIBA 01/2019
1	Histone Deacetylases (Histone Deacetylase)IBA 09/2017
1	Histone Deacetylase InhibitorsIBA 09/2017
1	Protein Isoforms (Isoforms)IBA 12/2016
1	Biomarkers (Surrogate Marker)IBA 03/2014
1	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 12/2012
1	AgarIBA 12/2012
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2011
1	Matrix Metalloproteinases (MMPs)IBA 05/2010
1	OligonucleotidesIBA 05/2010
1	AntigensIBA 08/2009
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 05/2009
1	Troglitazone (Rezulin)FDA Link 05/2009
1	PPAR gammaIBA 05/2009
1	2- hydroxy- N,N- dimethyl- 3- (2- ((1- (5- methylfuran- 2- yl)propyl)amino)- 3,4- dioxocyclobut- 1- enylamino)benzamideIBA 04/2009
1	2-Hydroxypropyl-beta-cyclodextrinIBA 04/2009
1	SCH 479833IBA 04/2009
1	RANK LigandIBA 01/2009
1	Transforming Growth Factor-beta Type I ReceptorIBA 01/2009
1	Phosphotransferases (Kinase)IBA 01/2009
1	plexinIBA 01/2007
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2007
1	Cell Adhesion MoleculesIBA 01/2007
1	Interleukin-8A Receptors (Receptors, Interleukin 8A)IBA 02/2006
1	Interleukin-8 ReceptorsIBA 01/2003
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 04/2002

Therapy/Procedure

11	Therapeutics 02/2022 - 01/2009
4	Drug Therapy (Chemotherapy) 01/2020 - 08/2007
1	Immunotherapy 08/2009
1	Stem Cell Transplantation 08/2007